Spondyloarthritis & psoriatic arthritis
Phase II randomised, placebo-controlled study to evaluate the efficacy and safety of an MK2 inhibitor in ankylosing spondylitis
- Study terminated based on futility at interim analysis
Authors' conclusion
Inhibition of MK2 by CC-99677 was insufficient to lead to significant clinical benefits in AS.
Study context
- Population
- Ankylosing spondylitis (AS) fulfilling modified New York criteria, active symptoms (BASDAI ≥4 and total back pain ≥4) despite ≥2 NSAIDs, bDMARD-naïve123 completed treatment
- Participants
- 147 participants
- Comparison
- Once-daily CC-99677 150 mg or 60 mg vs placebo
- Primary endpoint
- ASAS20 response
- Follow-up
- 12 weeks
Methodological detailsphase II, multicentre, double-blind, placebo-controlled
- Phase II
- Multicentre
- Double-blind
- Placebo-controlled
Primary result
As reported in the abstract
week 12
Secondary outcomes
ASAS40 response · week 12
Secondary end points
- No significant treatment group differences
MRI spine and sacroiliac joint inflammation scores; serum pro-inflammatory cytokines
- Trends in active treatment groups for improvement in MRI spine and sacroiliac joint inflammation scores
- Minimal inhibition of pro-inflammatory cytokines in serum
Original publication
Phase II randomised, placebo-controlled study to evaluate the efficacy and safety of an MK2 inhibitor in ankylosing spondylitis. RMD Open. Published 21 May 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →